AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04977349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: This group will be treated by manual therapy: suboccipital inhibition, myofascial extracavitary treatment in (superior trapezius fibers, ECOM, masseter and temporalis) and intracavitary muscles (medialis and lateral pterygoid muscles).
Study NCT04977349 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: This group will be treated by manual therapy: suboccipital inhibition, myofascial extracavitary treatment in (superior trapezius fibers, ECOM, masseter and temporalis) and intracavitary muscles (medialis and lateral pterygoid muscles).
Study NCT04977349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: Isometric exercises for: cranial protrusion, mouth opening, laterality cervical movement and cervical coordination by laser assessment. And the manual therapy from the Active Comparator group.
Study NCT04977349 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise program
Description: Isometric exercises for: cranial protrusion, mouth opening, laterality cervical movement and cervical coordination by laser assessment. And the manual therapy from the Active Comparator group.
Study NCT05704647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986213 (Relatlimab-Nivolumab FDC)
Description: Given by IV (vein)
Study NCT05704647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given by IV (vein)
Study NCT05704647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Given by IV (vein)
Study NCT05399433 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biopsy and venous blood
Description: A skin biopsy will be performed under local anesthesia in diabetic and non-diabetic psoriatic patients (25 per group) in the injured area (joint extension) and in the non-injured area more than 2 cm from any lesion in the same area. In patients in the diabetic or non-diabetic control group (25 per group) only one biopsy will be performed.~Peripheral venous blood will be collected in heparin tubes for metabolic parameter analysis and blood CD analysis
Study NCT05567315 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local anaesthetic injection
Description: Infiltration of 40 to 80 ml of a non-adrenalized 0.5% lidocaine solution into the vaginal wall at the level of the vaginal pouches, under ultrasound guidance. (within the limit of the toxic doses, i.e. 5mg/kg)
Study NCT04512378 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Experiments for Intolerance of Uncertainty
Description: Cognitive-behavioural treatment targeting intolerance of uncertainty using behavioural experiment technique
Study NCT06464640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Online Interactive Podcast Program Living with Type 1 Diabetes to Grown-Up
Description: The podcast content was designed based on the results of previous research.Subjects will be randomly assigned to either the experimental group (N=44) or the comparison group (N=44). Comparative analyses will focus on variations in disease control, emotional disturbance,confidence in self-management, self-care behaviors, diabetes knowledge,interpersonal disturbance, and family conflict at baseline, and post-interventions of immediate, 3-month, and 6-month periods.
Study NCT06464640 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: E-book
Description: Participants in the active control group will use Ebook.According to the research results from the project leader\&#39;s app effectiveness evaluation (Chiang, 2020-2022), the e-book did not show significant effects on blood sugar control, disease management confidence, self-care behaviors, disease-related knowledge, or interpersonal distress. Therefore, the active control group received a sham treatment in the form of an e-book. The research team extracted content from the CEO APP e-book, with an expert validity of 0.91, and reorganized it into an electronic health education manual titled \&#34;Transitioning from Adolescence to Early Adulthood: The Ins and Outs of Type 1 Diabetes.\&#34;
Study NCT05497024 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interviews
Description: Participants will discuss background, such as race, education, and living situation.~Participants will discuss Prostate cancer Participants will discuss feedback on the educational material
Study NCT05497024 — intervention group
Intervention type: BEHAVIORAL
Intervention: Surveys
Description: Participants may answer questions that are sensitive in nature.
Study NCT06640439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: photobiomodulation
Description: 830 nm LED was used to irradiate the post-extraction area
Study NCT06640439 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Antibiotic
Description: ibuprofen 0.3 g bid for 3 days, metronidazole 0.1 g tid, and cefaclor 0.375 g bid for 7 days after surgery
Study NCT06640439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic
Description: ibuprofen 0.3 g bid for 3 days, metronidazole 0.1 g tid, and cefaclor 0.375 g bid for 7 days after surgery
Study NCT06645275 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: POCT test
Description: Patients undergo POCT testing on the day of warfarin administration, and based on the POCT results, the initial and maintenance doses of warfarin are determined according to the IWPC algorithm.
Study NCT06496477 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ayo wearable
Description: Primary study device - the Ayo wearable which are glasses that emit either bright blue-spectrum white light or dim blue-spectrum white light or Mini motion logger AAM-32 - an actigraphy device work during the first and last week of the study on the participants wrist throughout most of the day, measuring activity. This will be used as an indicator of sleep.
Study NCT05567315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: local anaesthetic injection
Description: Infiltration of 40 to 80 ml of a non-adrenalized 0.5% lidocaine solution into the vaginal wall at the level of the vaginal pouches, under ultrasound guidance. (within the limit of the toxic doses, i.e. 5mg/kg)
Study NCT05567315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hypnosis with Virtual reality mask
Description: A 20-minute virtual reality hypnosis session is performed from the time the patient is placed on the surgical table until the end of the oocyte poncture
Study NCT04997278 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coordinated Reset spinal cord stimulation
Description: Abnormal neuronal synchrony in terms of enhanced 4-9 Hz theta oscillations in EEG/MEG recordings appears to be an important pathophysiological finding in patients with neurogenic pain. To specifically counteract abnormal neuronal synchrony, we here set out to perform Coordinated Reset (CR)-Spinal Cord Stimulation (SCS). CR stimulation (Tass, 2003) aims at an anti-kindling, i.e. an unlearning or resetting of abnormal neuronal synchrony and abnormal synaptic connectivity, and, hence, long-lasting, sustained therapeutic effects that persist following cessation of stimulation (Tass \& Majtanik, 2006).
Study NCT06147245 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-centred culturally sensitive course of treatment
Description: 12-month person-centred and culturally sensitive intervention: Participants will attend 6 visits at SDCC including visits with a diabetes nurse, physician and dietitian. The course of treatment is focusing on extended time in consultations, use of technology for diabetes monitoring, meeting the same healthcare professionals, awareness of language barriers and use of accurate communication and dialogue tools in participants native language.
Study NCT05884073 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circuit-based Resistance Training
Description: Participants will engage in a 12-week circuit-based resistance training program 2-3 times/week. Each supervised session will last about 30 minutes and will consist of 5 resistance exercises. Each exercise will be completed for 1 minute for a total of 5 minutes followed by a 1-minute rest. The circuit will then repeated 3 additional times (total of 4 circuits). All resistance sessions will be supervised by a certified fitness professionals.
Study NCT05884073 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nature-based Walking
Description: Participants will be asked to engage in 30 minutes of self-paced walking in nature 2-3 days/week. Participants will be provided with a list of resources that direct them to walkable nature/green spaces close to their home or workplace.
Study NCT05289544 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Phone-Based Walk With Ease
Description: 6 week phone-delivered Walk With Ease Program
Study NCT05289544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone-Based Walk With Ease
Description: 6 week phone-delivered Walk With Ease Program
Study NCT05487391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706 injection
Description: QL1706(5mg/kg Q3W IV) concomitantly with Platinum-based chemotherapy
Study NCT05487391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vinorelbine Tartrate
Description: Vinorelbine 25mg/m2（D1、D8）Q3W IV, 2-4 cycles
Study NCT05487391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine Tartrate
Description: Vinorelbine 25mg/m2（D1、D8）Q3W IV, 2-4 cycles
Study NCT06205823 — intervention group
Intervention type: DRUG
Intervention: Immunotherapy
Description: Immunotherapy
Study NCT06210204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth follow-up
Description: Patients to follow-up via phone after surgery
Study NCT05276687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betadine
Description: Wound irrigation
Study NCT05276687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: instillation in the wound
Study NCT05201079 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MBK-01
Description: A single dose of 4 capsules of MBK-01 (heterologous lyophilized fecal microbiota coming from healthy donors) orally.
Study NCT05201079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dificlir
Description: Oral administration of 200mg/12 hours of fidaxomicin for 10 days.
Study NCT05860387 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Next generation improvement of early invasive aspergillosis
Description: Next generation improvement of early invasive aspergillosis test is intended to determine the suitability of new potential biomarkers of aspergillosis.
Study NCT05034562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT05034562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68-labeled PSMA-11
Description: Given IV
Study NCT05034562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo PET/MRI
Study NCT05034562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT or PET/MRI
Study NCT04977674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Pre-treatment with naltrexone 45 min before the ketamine infusion.
Study NCT05300451 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab and hyaluronidase-fihj
Description: Daratumumab and hyaluronidase-fihj for subcutaneous (under the skin) injection has different dosing and administration instructions compared to daratumumab for intravenous (in the vein) infusion. Daratumumab and hyaluronidase-fihj contains recombinant hyaluronidase, which mimics hyaluronidase, a naturally occurring substance that increases permeability of subcutaneous tissue. This makes it possible for 15 mL containing 1,800 mg of daratumumab to be administered in approximately 3 to 5 minutes. Subjects will receive a 1800mg/30000u injection subcutaneously weekly for a total of 8 doses
Study NCT04789850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: 200 mg oral for 360 days
Study NCT04789850 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200 mg oral for 360 days
Study NCT05487391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 175mg/m2（D1） Q3W IV, 2-4 cycles
Study NCT05487391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 175mg/m2（D1） Q3W IV, 2-4 cycles
Study NCT05487391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 75mg/m2（D1）Q3W IV, 2-4 cycles
Study NCT05487391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75mg/m2（D1）Q3W IV, 2-4 cycles
Study NCT05487391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC=5（D1） Q3W IV, 2-4 cycles
Study NCT05108896 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 3-Screenings Protocol
Description: The 3-Screenings Protocol is a modified bedside swallow exam (BSE) consisting of a study developed five-item decision tree algorithm including voice quality assessment and a 2-ounce water consistency assessment, the Yale Swallow Test, with a scored 3-ounce Water Swallow Test (3-WST), and the Toronto Bedside Swallowing Screening Test (TOR-BSST).
Study NCT05487391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC=5（D1） Q3W IV, 2-4 cycles
Study NCT04977674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pre-treatment with placebo 45 min before the ketamine infusion.
Study NCT04977674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Participants receive intravenous ketamine infusion (0.5 mg/kg over 40 min) at both study visits.
Study NCT04651985 — intervention group
Intervention type: OTHER
Intervention: Eccentric strengthening exercises of the Achilles tendon
Description: This exercise will require the completion of slow active eccentric plantar flexion exercises with the forefoot positioned over the edge of a step. These exercises will be repeated twice daily (three sets of 15 repetitions with the knee in extension and three sets of 15 repetitions with the knee in flexion) during a three-month period. The amount of loading will be calibrated and progressed on a weekly basis by the physiotherapist according the participant's perceived effort and pain intensity.
Study NCT06557928 — intervention group
Intervention type: OTHER
Intervention: measurement
Description: Measurement of multiple physiological indicators and psychological status and multi-omics study
Study NCT05487391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed 500mg/m2（D1） Q3W IV, 2-4 cycles
Study NCT05487391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500mg/m2（D1） Q3W IV, 2-4 cycles
Study NCT04958668 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post-operative intensive care using volatile sedation
Description: Patients admitted after valve surgery are receiving intensive care using volatile sedative per anaesthetic conserving device. The subject of the study is medical and nursing time management..
Study NCT04599829 — intervention group
Intervention type: DEVICE
Intervention: AnkleSTRONG100/500/900
Description: At least 30 patients (15 patients in the orthosis group and 15 patients in the control group) per device type (3 device types: Ankle STRONG 100/500/900) totalling 90 patients will be included. Patients included in the orthosis group will use the device during sports sessions while patients included in the control group will not use an ankle support device.
Study NCT04548037 — intervention group
Intervention type: OTHER
Intervention: PET-CT examination
Description: The subject is placed in supine position, the head immobilized in a headrest. The imaging sequence begins with a scout view (viewing angle 90 °, 120 kV, 20 mA), then an X-ray scan is performed for the attenuation correction (120 kV, 5 mAs per slice, pitch 0.531, collimation 40 mm , FOV 70) and diagnostic CT scan (120 kV, 100-250 mA: auto mA, pitch 0.531, 40 MM, DFOV 25, ASIR 60%, thickness 1.25 mm). Finally, the positron emission tomography is acquired: static in 3D mode for 15 minutes, 30 minutes after the injection of 18 FDG, the axial field of view is 25, the matrix in 256 x 256, OSEM reconstruction 6 iterations 24 subsets, attenuation correction, diffused, and PSF. Gaussian filter, cutoff frequency of 4. Obtaining forty-seven contiguous sections of 3.26 mm thick.
Study NCT06232694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax : 100mg on day 1, 200mg on day 2, 400mg on days 3 to 8; oral administration;
Description: Induction Phase Regimen
Study NCT06232694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax (Venetoclax): 400mg on day 1 to day 7; oral administration;
Description: Consolidation therapy after remission
Study NCT06232694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: utologous stem cell transplantation (ASCT) /allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Description: Four cycles in total.Patients who meet the criteria for autologous stem cell transplantation (ASCT) during the treatment process can undergo ASCT.Patients who meet the transplantation criteria and have a suitable donor can undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Study NCT05108896 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FEES
Description: A thin, flexible endoscope designed for assessment of laryngeal structures is passed through the nose to the oropharynx, visualizing the laryngeal structures, and the base of tongue and the pharynx. If needed 4% topical lidocaine and/or oxymetazoline (Afrin) will be administered. Swallowing will then be evaluated directly with six food boluses of 5 ml each. All patients will be allowed to swallow spontaneously without a verbal command to swallow. Video of the examinations will be recorded and presence of dysphagia will be designated independently by 3 different observers (one pulmonary physician and two speech language pathologists (SLPs)). This procedure will take 5-10 minutes. The camera will then be removed.
Study NCT05108896 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Tracheal Ultrasound
Description: Ultrasound imaging of the trachea, measuring tracheal diameter and endotracheal tube (ETT) size ratio within 72 hours prior to extubation
Study NCT05842850 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric restriction intervention
Description: The intervention consist of 4-weeks limiting daily food intake to a window of 8 hours (8am to 4pm) and water-fasting for the remaining hours of the day. Participants (LBW NAFLD individuals only) will be instructed to eat a balanced diet according to the current dietary guidelines reduced by 20% calories to ensure energy deficit.
Study NCT05842850 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: No intervention
Study NCT05508776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 152020
Description: Film-coated tablet~Route of administration: Orally~50 mg tablets
Study NCT05508776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Tablet (may be film-coated depending on brand)~Route of administration: Orally~400 mg tablet
Study NCT05508776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet~Route of administration: Orally~No active ingredient
Study NCT06165692 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRF
Description: Post-operative PRF placement in the post-extraction socket after third molar surgery
Study NCT06019117 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic K10
Description: clinical trial using 90 days of probiotic K10
Study NCT06019117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: clinical trial using 90 days of placebo controlled
Study NCT05283330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ²¹²Pb-DOTAM-GRPR1
Description: ²¹²Pb-DOTAM-GRPR1 is a radioimmunoconjugate comprised of ²¹²Pb, the metal chelator DOTAM (1,4,7,10-Tetrakis(carbamoylmethyl)-1,4,7,10- tetraazacyclododecane) and a GRPR-targeted antagonist.
Study NCT04983342 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apollo Armband
Description: The Apollo armband is approximately the size of an Apple Watch and can be worn on the ankle, wrist, or arm with two adjustable fabric straps. Apollo vibrations activate touch receptors in the skin and are perceived as safety signals by the brain resulting in decreased stress, improved recovery, focus, and energy, combatting fatigue and pain. In addition to the wearable, Apollo is a software system that curates music for the body, rather than for the ears.
Study NCT05487391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05913427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG
Description: EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days.~Megestrol acetate will be prepared and packaged by the authorized external contract development and manufacturing organization (CDMO) Doppel Farmaceutici s.r.l. (Cortemaggiore, PC), that, according to the GMP and applicable law (FU XII ed) will also prepare the related placebo, in accordance with GMP (annex 13) and applicable law (FU XII ed.).